Roed Skarderud M, Polk A, Kjeldgaard Vistisen K, Larsen FO, Nielsen DL (2018) Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: a systematic review. Cancer Treat Rev 62:61–73. https://doi.org/10.1016/j.ctrv.2017.10.011

Article  CAS  PubMed  Google Scholar 

Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouche O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D, Group CS (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303–312. https://doi.org/10.1016/S0140-6736(12)61900-X

Article  CAS  PubMed  Google Scholar 

Yoshino T, Komatsu Y, Yamada Y, Yamazaki K, Tsuji A, Ura T, Grothey A, Van Cutsem E, Wagner A, Cihon F, Hamada Y, Ohtsu A (2015) Randomized phase III trial of regorafenib in metastatic colorectal cancer: analysis of the CORRECT Japanese and non-Japanese subpopulations. Investig New Drugs 33:740–750. https://doi.org/10.1007/s10637-014-0154-x

Article  CAS  Google Scholar 

Lipworth AD, Robert C, Zhu AX (2009) Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology 77:257–271. https://doi.org/10.1159/000258880

Article  CAS  PubMed  Google Scholar 

Lacouture ME, Reilly LM, Gerami P, Guitart J (2008) Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 19:1955–1961. https://doi.org/10.1093/annonc/mdn389

Article  CAS  PubMed  Google Scholar 

Kubota Y, Fujita KI, Takahashi T, Sunakawa Y, Ishida H, Hamada K, Ichikawa W, Tsunoda T, Shimada K, Masuo Y, Kato Y, Sasaki Y (2020) Higher systemic exposure to unbound active metabolites of regorafenib is associated with short progression-free survival in colorectal cancer patients. Clin Pharmacol Ther 108:586–595. https://doi.org/10.1002/cpt.1810

Article  CAS  PubMed  Google Scholar 

Ding F, Liu B, Wang Y (2020) Risk of hand-foot skin reaction associated with vascular endothelial growth factor-tyrosine kinase inhibitors: a meta-analysis of 57 randomized controlled trials involving 24,956 patients. J Am Acad Dermatol 83:788–796. https://doi.org/10.1016/j.jaad.2019.04.021

Article  CAS  PubMed  Google Scholar 

Azad NS, Aragon-Ching JB, Dahut WL, Gutierrez M, Figg WD, Jain L, Steinberg SM, Turner ML, Kohn EC, Kong HH (2009) Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy. Clin Cancer Res 15:1411–1416. https://doi.org/10.1158/1078-0432.CCR-08-1141

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hasan Alshammari A, Masuo Y, Fujita KI, Shimada K, Iida N, Wakayama T, Kato Y (2022) Discrimination of hand-foot skin reaction caused by tyrosine kinase inhibitors based on direct keratinocyte toxicity and vascular endothelial growth factor receptor-2 inhibition. Biochem Pharmacol 197:114914. https://doi.org/10.1016/j.bcp.2022.114914

Article  CAS  PubMed  Google Scholar 

Apte RS, Chen DS, Ferrara N (2019) VEGF in signaling and disease: beyond discovery and development. Cell 176:1248–1264. https://doi.org/10.1016/j.cell.2019.01.021

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gurtner GC, Werner S, Barrandon Y, Longaker MT (2008) Wound repair and regeneration. Nature 453:314–321. https://doi.org/10.1038/nature07039

Article  ADS  CAS  PubMed  Google Scholar 

Singer AJ, Clark RA (1999) Cutaneous wound healing. N Engl J Med 341:738–746. https://doi.org/10.1056/NEJM199909023411006

Article  CAS  PubMed  Google Scholar 

Suenaga M, Mashima T, Kawata N, Wakatsuki T, Horiike Y, Matsusaka S, Dan S, Shinozaki E, Seimiya H, Mizunuma N, Yamaguchi K, Yamaguchi T (2016) Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer. Oncotarget 7:34811–34823. https://doi.org/10.18632/oncotarget.9187

Article  PubMed  PubMed Central  Google Scholar 

Wang SW, Liu SC, Sun HL, Huang TY, Chan CH, Yang CY, Yeh HI, Huang YL, Chou WY, Lin YM, Tang CH (2015) CCL5/CCR5 axis induces vascular endothelial growth factor-mediated tumor angiogenesis in human osteosarcoma microenvironment. Carcinogenesis 36:104–114. https://doi.org/10.1093/carcin/bgu218

Article  CAS  PubMed  Google Scholar 

dbSNP National Center for Biotechnology Information. https://www.ncbi.nlm.nih.gov/snp/. Accessed 10 Aug 2023

Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Ning Y, Cremolini C, Antoniotti C, Borelli B, Mashima T, Okazaki S, Berger MD, Miyamoto Y, Gopez R Jr, Barzi A, Lonardi S, Yamaguchi T, Falcone A, Loupakis F, Lenz HJ (2018) Gene polymorphisms in the CCL5/CCR5 pathway as a genetic biomarker for outcome and hand-foot skin reaction in metastatic colorectal cancer patients treated with regorafenib. Clin Colorectal Cancer 17:e395–e414. https://doi.org/10.1016/j.clcc.2018.02.010

Article  PubMed  PubMed Central  Google Scholar 

Howard OM, Turpin JA, Goldman R, Modi WS (2004) Functional redundancy of the human CCL4 and CCL4L1 chemokine genes. Biochem Biophys Res Commun 320:927–931. https://doi.org/10.1016/j.bbrc.2004.06.039

Article  CAS  PubMed  Google Scholar 

Colobran R, Adreani P, Ashhab Y, Llano A, Este JA, Dominguez O, Pujol-Borrell R, Juan M (2005) Multiple products derived from two CCL4 loci: high incidence of a new polymorphism in HIV+ patients. J Immunol 174:5655–5664. https://doi.org/10.4049/jimmunol.174.9.5655

Article  CAS  PubMed  Google Scholar 

Kobayashi K, Kawakami K, Yokokawa T, Aoyama T, Suzuki K, Wakatsuki T, Suenaga M, Sato H, Sugiyama E, Yamaguchi K, Hama T (2019) Association of hand-foot skin reaction with regorafenib efficacy in the treatment of metastatic colorectal cancer. Oncology 96:200–206. https://doi.org/10.1159/000495989

Article  CAS  PubMed  Google Scholar 

Argiles G, Mulet N, Valladares-Ayerbes M, Vieitez JM, Gravalos C, Garcia-Alfonso P, Santos C, Tobena M, Garcia-Paredes B, Benavides M, Cano MT, Loupakis F, Rodriguez-Garrote M, Rivera F, Goldberg RM, Cremolini C, Bennouna J, Ciardiello F, Tabernero JM, Aranda E, Spanish Cooperative Group for the Treatment of Digestive T, Unicancer GI, The Ri, Principal i, Argiles G, Tabernero J, Steering C, Investigators (2022) A randomised phase 2 study comparing different dose approaches of induction treatment of regorafenib in previously treated metastatic colorectal cancer patients (REARRANGE trial). Eur J Cancer 177:154–163. https://doi.org/10.1016/j.ejca.2022.09.037

Article  CAS  PubMed  Google Scholar 

Bekaii-Saab TS, Ou FS, Ahn DH, Boland PM, Ciombor KK, Heying EN, Dockter TJ, Jacobs NL, Pasche BC, Cleary JM, Meyers JP, Desnoyers RJ, McCune JS, Pedersen K, Barzi A, Chiorean EG, Sloan J, Lacouture ME, Lenz HJ, Grothey A (2019) Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study. Lancet Oncol 20:1070–1082. https://doi.org/10.1016/S1470-2045(19)30272-4

Article  CAS  PubMed  PubMed Central  Google Scholar